Abstract | AIMS: To evaluate the effect of short-term administration of the anti-lipolytic agent, Acipimox, on the ability of plasma to stimulate cellular cholesterol removal, which represents one of the first steps in the anti-atherogenic process of reverse cholesterol transport. METHODS: RESULTS:
Acipimox lowered plasma triglycerides in diabetic patients (P = 0.001) and healthy subjects (P = 0.002), whereas plasma non- esterified fatty acids were decreased in diabetic patients (P = 0.001) compared with the averaged values at baseline and recovery. Acipimox decreased HDL cholesterol in healthy subjects (P = 0.007) and plasma apolipoprotein AI in both groups (P = 0.001 for diabetic patients; P = 0.008 for healthy subjects). Not only plasma PLTP activity (P = 0.001 for diabetic patients; P = 0.01 for healthy subjects), but also pre-beta HDL in incubated plasma (P = 0.001 for diabetic patients; P = 0.03 for healthy subjects) and cellular cholesterol efflux to plasma (P = 0.04 for diabetic patients; P = 0.005 for healthy subjects) were lowered by Acipimox in both groups. CONCLUSIONS: Short-term Acipimox administration impairs the ability of plasma from Type 2 diabetic patients and healthy subjects to stimulate cellular cholesterol efflux, in conjunction with alterations in HDL parameters and in PLTP activity. If the impairment of cellular cholesterol efflux to plasma is sustained with long-term treatment, this potentially adverse effect should be considered when treating diabetic dyslipidaemia with Acipimox. Diabet. Med. 18, 509-513 (2001)
|
Authors | R P Dullaart, A van Tol |
Journal | Diabetic medicine : a journal of the British Diabetic Association
(Diabet Med)
Vol. 18
Issue 6
Pg. 509-13
(Jun 2001)
ISSN: 0742-3071 [Print] England |
PMID | 11472472
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Apolipoprotein A-I
- Carrier Proteins
- Cholesterol, HDL
- Fatty Acids, Nonesterified
- High-Density Lipoproteins, Pre-beta
- Hypolipidemic Agents
- Lipoproteins, HDL
- Membrane Proteins
- Phospholipid Transfer Proteins
- Pyrazines
- Cholesterol
- acipimox
|
Topics |
- Animals
- Apolipoprotein A-I
(blood)
- Body Mass Index
- Carrier Proteins
(blood)
- Cholesterol
(blood, metabolism)
- Cholesterol, HDL
(blood)
- Diabetes Mellitus, Type 2
(blood)
- Fatty Acids, Nonesterified
(blood)
- High-Density Lipoproteins, Pre-beta
- Humans
- Hypolipidemic Agents
(pharmacology, therapeutic use)
- Lipoproteins, HDL
(blood)
- Liver Neoplasms, Experimental
- Male
- Membrane Proteins
(blood)
- Middle Aged
- Phospholipid Transfer Proteins
- Pyrazines
(pharmacology, therapeutic use)
- Rats
- Reference Values
- Tumor Cells, Cultured
|